Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort
nICRT followed by surgery may lead to a promising pathological response. For patients with lymph node metastasis in certain regions, nICRT should be considered as a better preoperative treatment option.
Authors
- Wei‐Xiang Qi (ORCID: https://orcid.org/0000-0001-5484-3343)
- Xiaotao Han (ORCID: https://orcid.org/0000-0002-7089-9598)
- Jiayi Chen (ORCID: https://orcid.org/0000-0001-6417-290X)
- Shuyan Li (ORCID: https://orcid.org/0000-0001-7028-4166)
- Huan Li (ORCID: https://orcid.org/0009-0004-2695-6825)
- Shengguang Zhao (ORCID: https://orcid.org/0000-0002-4197-8887)
Institutions
- Ruijin Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1700400
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission